187 related articles for article (PubMed ID: 28576947)
1. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
2. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A; Vultur A; Bogeski I; Wang H; Zimmermann KM; Speicher D; Körbel C; Laschke MW; Gimotty PA; Philipp SE; Krause E; Pätzold S; Villanueva J; Krepler C; Fukunaga-Kalabis M; Hoth M; Bastian BC; Vogt T; Herlyn M
Cancer Cell; 2013 Jun; 23(6):811-25. PubMed ID: 23764003
[TBL] [Abstract][Full Text] [Related]
3. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
5. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
6. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
8. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.
Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
Melanoma Res; 2013 Oct; 23(5):360-5. PubMed ID: 23921446
[TBL] [Abstract][Full Text] [Related]
9. Targeting invasive properties of melanoma cells.
Arozarena I; Wellbrock C
FEBS J; 2017 Jul; 284(14):2148-2162. PubMed ID: 28196297
[TBL] [Abstract][Full Text] [Related]
10. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
11. Metabolic rewiring in melanoma drug-resistant cells.
Bristot IJ; Kehl Dias C; Chapola H; Parsons RB; Klamt F
Crit Rev Oncol Hematol; 2020 Sep; 153():102995. PubMed ID: 32569852
[TBL] [Abstract][Full Text] [Related]
12. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Verfaillie A; Imrichova H; Atak ZK; Dewaele M; Rambow F; Hulselmans G; Christiaens V; Svetlichnyy D; Luciani F; Van den Mooter L; Claerhout S; Fiers M; Journe F; Ghanem GE; Herrmann C; Halder G; Marine JC; Aerts S
Nat Commun; 2015 Apr; 6():6683. PubMed ID: 25865119
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
14. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.
Poindexter KM; Matthew S; Aronchik I; Firestone GL
Cell Biol Toxicol; 2016 Apr; 32(2):103-19. PubMed ID: 27055402
[TBL] [Abstract][Full Text] [Related]
15. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Roesch A; Fukunaga-Kalabis M; Schmidt EC; Zabierowski SE; Brafford PA; Vultur A; Basu D; Gimotty P; Vogt T; Herlyn M
Cell; 2010 May; 141(4):583-94. PubMed ID: 20478252
[TBL] [Abstract][Full Text] [Related]
16. ABCB5 is activated by MITF and β-catenin and is associated with melanoma differentiation.
Louphrasitthiphol P; Chauhan J; Goding CR
Pigment Cell Melanoma Res; 2020 Jan; 33(1):112-118. PubMed ID: 31595650
[TBL] [Abstract][Full Text] [Related]
17. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
18. Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
Zhang K; Wong P; Salvaggio C; Salhi A; Osman I; Bedogni B
J Invest Dermatol; 2016 Feb; 136(2):464-472. PubMed ID: 26967479
[TBL] [Abstract][Full Text] [Related]
19. Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling.
Golan T; Levy C
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699982
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
